Aarti Drugs Limited · NSE:AARTIDRUGS
Aarti Drugs — Investor Presentation (May 2015)
22 slides from Aarti Drugs's investor presentation, May 25, 2015
Slide 1: Aarti Drugs Ltd Corporate Presentation
Aarti Drugs Ltd Corporate Presentation May 25, 2015 (update)
Slide 2: Disclaimer
Disclaimer Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward looking statements that involve a number of risks and uncertainties. Although Aarti Drugs attempts to be accurate i
Slide 3: About Aarti Drugs
About Aarti Drugs OVERVIEW Part of the $ 650 million Aarti Group of Industries, the company was established back in 1984 It is engaged in manufacturing of APIs, Pharma Intermediates and specialty chemicals with 10 multi- ton, multi-location GMP compliant facilities 8 facilities located in Indu
Slide 4: About Aarti Drugs (Cont.)
About Aarti Drugs (Cont.) Various products are registered with various authorities like USFDA, COS, IDL, JAPAN ACCREDITATION, TGA, COFEPRIS, ANVISA, WHO-GMP, EUGMP It has developed 30 new molecules in the past five years AWARDS & RECOGNITION Year Authority Awards 2013 ABBOTT Best Vendor of the y
Slide 5: Vision and Mission
About Aarti Drugs Vision To be the preferred vendor for products in India and World Mission Seek global market leadership Focus on growth and development of the product Continue to create winning culture, operating in highest standards of ethics and values with co- operation among competitor
Slide 6: Shareholding structure
Shareholding structure Promoters Shareholding 70.00% 60.00% 50.00% 40.00% 30.00% 20.00% 10.00% 0.00% 55.57% 57.43% 59.61% 60.10% FY 11-12 FY 12-13 FY 13-14 FY 14-15 = Promoters Public & Others
Slide 7: Timelines
Timelines 2014 – Turnover of Rs. 1000 Crore 2010- Turnover of RS. 500 Crore 2008- Approval of USFDA Plant 1997- Turnover of Rs. 100 Crore 1996 – Amalgamation of RCIL, RCPL, MCPL, MPPL & EPCL 1993- Listed On Stock Exchange (BSE & NSE) 1984 - Incorporation
Slide 8: Leadership Team
Leadership Team Founder Director of Aarti Drugs Ltd Mr. Prakash M. Patil Excels in an array of promotional activities viz : product identification, project conceptualization, Chairman, MD & CEO planning, project engineering & project implementation Bachelor of Chemical Engineering From UDCT Mr
Slide 9: Business overview
Business overview Segmentwise Sales For FY 14-15 API's @Formulation | SpecialityChemicals Intermediates & others Therapeuticwise Sales for FY 14-15 @ Antibiotic @ Antiprotozoals @ Antiinflammatory @ Antifungal § Antidiabetic @ Cardioprotectant ™ Others Segmentwise Sales For FY 13-14 @APIs Formulatio
Slide 10: Business overview
Business overview • ADL is domestic market share leader in most of its top 10 products • Top 10 Local Clientele contributes to around 28% of total local sales • Export Clientele is well diversified with the topmost client contributing to only 3.77% of total export sales • Top 10 Export clients contr
Slide 11: Geographic presence
Geographic presence TOP 10 EXPORT COUNTRIES : Regulated 60% Country Country Semi-Regulated 10% BRAZIL TURKEY Non - Regulated 30% MEXICO BANGLADESH NETHERLANDS SPAIN EGYPT CHINA IRAN PAKISTAN
Slide 12: Key local clientele
Key local clientele Sr. No. Customer Name % To Total Local Sales 1 J.B. Chemicals & Pharmaceuticals Ltd 4.48% 2 Cipla Limited 4.43% 3 Alkem Laboratories Ltd 3.66% 4 Abbott Healthcare Pvt Ltd 3.33% 5 Zydus Healthcare Ltd 2.43% 6 Hetero Labs Ltd 2.28% 7 Zoetis India Limited (Pfizer) 2.12% 8 Micro Labs
Slide 13: Overview of facilities
Overview of facilities As of August 2014 Sr. No. Name of Unit Certification Australian Government – Department of Health and Ageing - Therapeutic Goods Administration 1. Aarti Drugs Ltd.E-22 WHO-GMP / Japanese Accreditation USFDA * Import alert dated 23rd Mar’15 ANVISA-Brazil 2 Aarti Drugs Ltd.G-60
Slide 14: Overview of facilities: Reaction Capabilities
Overview of facilities Reaction Capabilities Nitration Sulphonation Cyclocondensation Alkylation Ammonolysis (Amidation ) Methoxylation Epoxidation (Chiral & Achiral) Halogenation (CI, Br, I) Reduction Acetylation Dehalohydrogenation Diazotization & Related Chemistry Conden
Slide 15: Focus on quality
Focus on quality Establish and maintain high standards of quality of its products manufactured at various locations including those at contract manufacturing sites, meeting cGMP & cGLP norms Comply with current national and international regulations as applicable and continuously move towards me
Slide 16: R&D focus
R&D focus Manufacturing facilities supported by R&D team which is located at Tarapur Strength at R&D • Doctorates : 03 • Master Graduates [M. Sc] : 36 • Graduates [B. Sc] : 11 • Engineers : 25 • Technicians : 12 Pilot plant facility at corporate R&D center in Tarapur, which is suitable to manu
Slide 17: Future business strategy
Future business strategy Anti Diabetic: • Re ei ed EC appro al i April’15. Co er ial operatio s ill start y e d of 1st Qtr • Expected revenues of installed capacity would be ~150 cr per annum as per ROW market pricing. Designed for highly regulated markets. Layout has been designed for doubling th
Slide 18: Future business strategy – contd
Future business strategy – contd…… Vitamins / Anti-Inflammatory: • Multi-purpose facility under construction. Targeting highly regulated markets • Installed capacity will give revenues of around 50 Cr/ 35 Cr per annum as per product selection - Currently on HOLD R&D product pipeline: • Strong pi
Slide 19: Summary of financials - 1
Summary of financials - 1 Turnover Profit Before Tax & proft After Tax 1400 120 1200 1169.94 100.06 1044.35 en 699.18 ae 800 - 600 400 200 0 FY 11-12 FY 12-13 FY 13-14 FY 14-15 FY11-12 FY 12-13 FY 13-14 FY14-15 mein Crore @RsinCrore mRsin Crore Networth Earning Per Share (Bonus Issue 1:1 on 26-Mar-1
Slide 20: Summary of financials - 2
Summary of financials - 2 Book Value (Bonus Issue 1:1 on 26-Mar-15) Dividend Payout 140 30 L 26.95 26.77 25.51 34.96 103.61 25 100 85.73 20 80 72.88 Ki 15 40 10 20 5 0 C) FY 11-12 FY 12-13 FY 13-14 FY 14-15 FY 11-12 FY 12-13 FY 13-14 FY 14-15 = Amount in Rs mRsinCrore m% Return on Capital Employed R
Slide 21: Summary of financials - 3
Summary of financials - 3 Financial Overview (Rs in crores) Audited Mar '12 Mar '13 Mar '14 Mar '15 Equity Share Capital 12.11 12.11 12.11 24.22 Reserves 164.37 195.50 238.80 279.48 Net worth 176.48 207.61 250.91 303.70 Secured Loans 209.72 240.22 284.96 331.92 Unsecured Loans 88.20 80.29 93.73 102.
Slide 22: Website and contact information
Please visit our website for additional information like Annual Reports & addresses of registered offices: Website: www.aartidrugs.com For any further information please contact us at: Aarti Drugs Ltd Mahendra Inds. Estate, Ground Floor, Plot No. 109-D Road No. 29, Sion (E), Mumbai-400 022 (India) T